رجوع
نطاق اليوم
KWD 12.51
KWD 13.80
نطاق 52 أسبوعًا
KWD 5.68
KWD 16.74
حجم التداول
1,207,980
متوسط 50 يوم / 200 يوم
KWD 12.96
/
KWD 9.43
الإغلاق السابق
KWD 12.74
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -3.5 | 0.4 |
| P/B | 1.9 | 2.9 |
| ROE % | -44.0 | 3.8 |
| Net Margin % | — | 3.9 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.0 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 30.430
+137.0%
Low: KWD 26.000
High: KWD 38.000
ربحية السهم المستقبلية
-KWD 3.017
الإيرادات المقدّرة
27 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
-KWD 0.923
-KWD 1.785 – KWD 0.011
|
280 M | 2 |
| FY2029 |
-KWD 2.970
-KWD 5.743 – KWD 0.034
|
70 M | 4 |
| FY2028 |
-KWD 2.525
-KWD 3.240 – -KWD 1.873
|
52 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,582 | KWD 14.470 | KWD 66,302 |
| Feb 24, 2026 |
AHMED NADIM
President and CEO
|
sell | 13,515 | KWD 14.470 | KWD 195,562 |
| Feb 20, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
sell | 4,398 | KWD 13.620 | KWD 59,901 |
| Feb 20, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,982 | KWD 13.620 | KWD 67,855 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 11,742 | KWD 13.620 | KWD 165,366 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
other | 16,000 | KWD 4.300 | — |
| Feb 18, 2026 |
Savill Corrine
Chief Business Officer
|
grant | 175,000 | — | — |
| Feb 18, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
grant | 300,000 | — | — |
| Feb 18, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 206,250 | — | — |
| Feb 18, 2026 |
SUMER JACQUELYN L
Chief Legal Officer
|
grant | 230,000 | — | — |
| Feb 12, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 416 | KWD 12.030 | KWD 5,004 |
| Jan 22, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 4,000 | KWD 12.300 | KWD 49,200 |
| Dec 31, 2025 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 27 | KWD 6.490 | KWD 175 |
| Dec 23, 2025 |
AHMED NADIM
President and CEO
|
sell | 9,922 | KWD 10.010 | KWD 99,319 |
| Dec 19, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 1,345 | KWD 10.010 | KWD 13,463 |
| Dec 18, 2025 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,632 | KWD 9.670 | KWD 44,791 |
| Dec 18, 2025 |
SUMER JACQUELYN L
Chief Legal Officer
|
sell | 3,480 | KWD 9.670 | KWD 33,652 |
| Dec 18, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2,898 | KWD 9.670 | KWD 28,024 |
| Dec 15, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 995 | KWD 11.900 | KWD 11,841 |
| Dec 12, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2,148 | KWD 12.380 | KWD 26,592 |
النقاط الرئيسية
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -175.80M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-44.02%
ROIC-44.05%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
0.01
Current Ratio10.25
Interest Coverage0.00
التقييم
P/E Ratio
-3.53
P/B Ratio1.90
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -219.88M |
| ROE | -44.02% | ROA | -49.04% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -175.80M |
| ROIC | -44.05% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 10.25 |
| Interest Coverage | 0.00 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -3.53 | P/B Ratio | 1.90 |
| P/S Ratio | N/A | PEG Ratio | -0.14 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 777.16M | Enterprise Value | 691.51M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 18.94M |
| Net Income | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
| EPS (Diluted) | -3.72 | -3.11 | -3.69 | 2.38 | -1.48 |
| Gross Profit | -311,000.0 | -306,000.0 | 0.0 | 0.0 | 18.94M |
| Operating Income | -241.65M | -196.92M | -191.09M | 144.65M | -67.95M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Total Liabilities | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Shareholders' Equity | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
| Total Debt | 2.68M | 2.15M | 3.59M | 5.19M | 0.0 |
| Cash & Equivalents | 88.33M | 83.01M | 98.43M | 156.15M | 59.77M |
| Current Assets | 386.76M | 414.67M | 480.19M | 474.47M | 296.56M |
| Current Liabilities | 37.74M | 30.65M | 28.14M | 22.50M | 11.75M |